查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012614

化合物管理市场：2026-2032年全球市场预测（依最终用户、化合物类型、应用和自动化程度划分）

Compound Management Market by End User, Compound Type, Application, Automation Level - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，复合管理市场价值将达到 14.5 亿美元，到 2026 年将成长到 17.1 亿美元，到 2032 年将达到 44.5 亿美元，复合年增长率为 17.28%。

主要市场统计数据
基准年 2025 14.5亿美元
预计年份：2026年 17.1亿美元
预测年份 2032 44.5亿美元
复合年增长率 (%) 17.28%

本文简要概述了化合物管理的发展现状，重点在于重组实验室工作流程的技术、材料和操作方面的挑战。

目前化合物管理的现状是高通量科学、精准操作以及日益复杂的供应链动态三者交汇融合的结果。自动化、样品完整性监控和数位化库存管理等领域的最新技术进步，重新定义了科研机构和商业性研发部门对准确性、速度和可追溯性的期望。同时，随着治疗方法朝向生物製药、细胞和基因疗法的转变，传统平台无法充分满足新的物料处理需求，亟需专门设计的解决方案。

自动化、生物製药的复杂性以及数据驱动的互通性如何将化合物管理重新定义为策略性实验室职能。

在技​​术和科学趋势融合的驱动下，化合物管理领域正经历着变革性的转变。自动化不再局限于机械化，而是发展成为整合化的工作流程，其中机器人、环境控制系统和实验室资讯管理系统能够无缝协作。这种整合降低了人工干预和错误率，并实现了可扩展的样品处理能力，同时也提升了系统互通性和供应商协作的重要性。同时，复杂生物製药、基因疗法和细胞衍生产品的兴起，对储存、处理和可追溯性提出了新的要求，而传统的以小分子为中心的系统无法满足这些要求。

应对营运和采购中的关税波动，正在重塑研究机构的供应商策略、库存管理实践和国际合作。

2025年推出的关税政策趋势正在对采购、合约签订和跨国科研合作等各个领域造成实际压力。某些实验室设备、耗材和化学品的进口关税提高，迫使许多机构重新评估其供应商组合併重新谈判合同，以维持营运的连续性。因此，采购团队正与科学研究部门负责人更紧密合作，优先储备关键物资，探索替代供应商，并选择区域分销商，以降低对单一供应商的依赖风险。

基于详细细分的洞察，揭示了每个最终用户、化合物类型、应用和自动化层级的不同需求，从而指导策略性产品和服务的最佳化。

细分市场洞察揭示了不同的需求和部署模式，这些模式都应指南产品开发、服务模式和市场策略。从最终用户的观点来看，学术和研究机构通常优先考虑柔软性、成本效益以及与各种仪器的开放式集成，而製药公司则寻求检验、扩充性且具有强大合规能力并致力于长期服务交付的系统。生技公司通常需要能够适应专案范围快速变化的模组化解决方案，而受託研究机构(CRO) 则优先考虑高通量能力和标准化工作流程，以服务多个客户。政府和监管机构则强调用于监测和公共卫生研究的样本的监管炼和长期存檔完整性。

区域科学生态系统和法规环境如何影响全球市场中化合物管理重点、支援模式和自动化采用。

区域趋势影响企业在化合物管理方面对投资、伙伴关係和营运韧性的优先顺序。美洲地区集中了许多大规模製药研发中心和成熟的生物技术生态系统，推动了对高通量、检验的系统和服务模式的需求，以支持受监管的研发。该地区还拥有活跃的整合服务和本地化支援网路的售后市场，促使供应商提供长期服务合约和客製化方案。欧洲、中东和非洲（EMEA）地区呈现出多元化的环境，跨国公司与国家研究机构和新兴生物技术企业并肩运作。欧洲部分地区的监管协调与其它地区特定的采购规则形成鲜明对比，影响自动化和先进库存管理系统的采用曲线。在该地区，需要在跨境合作和当地监管限制之间取得平衡，这凸显了企业对合规模块化解决方案的浓厚兴趣。

竞争与伙伴关係趋势揭示了硬体、软体和服务的整合，以及以应用为中心的创新，如何塑造供应商差异化和客户维繫。

对主要企业的分析着重于策略定位、伙伴关係模式以及差异化优势显着的领域。市场领导凭藉着强大的硬体产品组合、扩充性的软体平台和成熟的服务交付能力，最能赢得需要长期检验和运作保证的企业级专案。同时，新兴供应商透过提供模组化、可升级的架构，降低了中型检查室的自动化门槛，并透过开放API强调互通性，从而促进与实验室资讯管理系统（LIMS）的集成，并因此获得了市场认可。随着企业努力提供提案安装、检验、维护和资料管理的端到端伙伴关係，设备製造商、软体供应商和第三方服务机构之间的策略合作伙伴关係日益普遍。

为高阶主管提供可操作的策略重点，以增强复合管理环境中的互通性、供应链弹性和数据驱动营运。

产业领导者应采取果断行动，使化合物管理能力与科学策略和营运韧性保持一致。首先，高阶主管在评估新设备时应优先考虑互通性和模组化，确保投资能够随着科学重点的变化而扩展或重新利用。其次，应建立包括采购、科学研究营运、品质和IT在内的跨职能管治架构，以简化供应商合格、管理价格和供应链风险并执行资料完整性标准。第三，各组织应试点利用分析和物联网驱动的诊断能力开展数据驱动型倡议，以减少意外停机时间并优化试剂利用率，从而在提高产量的同时降低营运风险。

透过严谨的混合方法，结合对从业者的访谈、技术文献的审查和专家检验，获得了切实可行的操作见解和策略建议。

本执行摘要的调查方法结合了第一手资料和第二手资料，系统地审查了这两类信息，以确保其相关性和实用性。一级资讯来源包括对学术机构、生物技术公司、受託研究机构、政府机构和製药公司的实验室经理、检查室经理和技术负责人的访谈，从而直接了解实际操作中的挑战和采购实践。第二手资料包括供应商的技术文献（说明了小分子化合物和复杂生物製药处理要求的演变）、监管指导文件、同行评审文章以及关于自动化和数据集成最佳实践的白皮书。

一项具有前瞻性的综合分析，解释了为什么化合物管理是研发机构提高研究速度、样品完整性和监管准备度的策略驱动因素。

总之，化合物管理已从一项主要由行政部门主导的后勤部门职能发展成为一项策略能力，对调查速度、资料完整性和监管准备有显着影响。自动化技术的进步、生物製药和细胞/基因疗法日益增长的重要性，以及对数据驱动的维护和库存管理的日益重视，都促进了系统互通性、环境管理和服务可靠性标准的提升。积极整合采购、科研营运和IT职能的机构将更有利于最大限度地发挥现代化合物管理系统带来的生产力提升，并降低供应链波动和监管审查带来的风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：化合物管理市场：依最终用户划分

  • 学术和研究机构
  • 生技公司
  • 合约研究机构
  • 政府/监管机构
  • 製药公司

第九章：依化合物类型分類的化合物管理市场

  • 生技药品
    • 细胞治疗产品
    • 基因治疗产品
    • 单株抗体
    • 重组蛋白
    • 疫苗
  • 核苷酸
  • 胜肽
  • 低分子化合物

第十章：化合物管理市场：依应用划分

  • 杀虫剂
  • 药物发现
    • 命中识别
    • 先导药物最适化
    • 临床前研究
    • 目标检验
  • 材料科学
  • 特种化学品

第十一章：化合物管理市场：依自动化程度划分

  • 全自动系统
  • 手动系统
  • 半自动系统

第十二章：复合管理市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：复合管理市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：复合管理市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国复合管理市场

第十六章：中国复合管理市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Arctoris Ltd.
  • AXXAM SpA
  • Azenta US, Inc.
  • Beckman Coulter Life Sciences
  • BioAscent Discovery Ltd.
  • BioIVT
  • Biosero Inc.
  • Brooks Automation, Inc.
  • ChemBridge Corporation
  • ChemDiv Inc.
  • Collaborative Drug Discovery
  • Compound Management Group
  • Danaher Corporation
  • Evotec SE
  • Hamilton Company
  • HighRes Biosolutions Inc.
  • Labcyte Inc.
  • LiCONiC AG
  • OpenEye Scientific Software, Inc.
  • PerkinElmer, Inc.
  • SPT Labtech Ltd.
  • Tecan Group Ltd.
  • Titian Service Limited
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-436BDB26AFD9

The Compound Management Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.71 billion in 2026, with a CAGR of 17.28%, reaching USD 4.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.71 billion
Forecast Year [2032] USD 4.45 billion
CAGR (%) 17.28%

A concise framing of the evolving compound management landscape emphasizing technological, material, and operational pressures reshaping laboratory workflows

The compound management landscape sits at the intersection of high-throughput science, precision handling, and increasingly complex supply chain dynamics. Recent technological advances in automation, sample integrity monitoring, and digital inventory control have redefined expectations for accuracy, speed, and traceability across research organizations and commercial R&D. At the same time, shifts in therapeutic modalities toward biologics and cell and gene therapies have introduced new material handling requirements that challenge legacy platforms and demand purpose-built solutions.

Consequently, leaders must reconcile the need for robust, compliant compound custody with pressures to increase throughput and lower operational risk. This introduction synthesizes the forces reshaping compound management, clarifies where value is being created, and frames the strategic questions organizational leaders should prioritize. By establishing a shared baseline, decision-makers can evaluate technology investments, partnerships, and process redesigns with greater confidence and align compound handling capabilities to broader scientific and regulatory objectives.

How automation, biologics complexity, and data-driven interoperability are redefining compound management as a strategic laboratory capability

The landscape for compound management is undergoing transformative shifts driven by converging technological and scientific trends. Automation is maturing beyond mechanization into integrated workflows where robotics, environmental controls, and laboratory information management systems operate as a synchronized whole. This integration reduces manual touchpoints and error rates while enabling scalable sample throughput, yet it also increases the importance of systems interoperability and vendor collaboration. Simultaneously, the rise of complex biologics, gene therapies, and cell-based products imposes new storage, handling, and traceability requirements that legacy small-molecule-focused systems were not designed to satisfy.

In parallel, data-centric approaches are changing how organizations manage compound inventories. Advanced analytics and predictive maintenance improve uptime and reduce reagent waste, and digital audit trails enhance regulatory readiness. Moreover, partnerships between instrument manufacturers and software providers are accelerating the pace at which laboratories can adopt modular, upgradeable systems. Taken together, these shifts mean that compound management is no longer a back-office function; it is a strategic capability that underpins faster, safer, and more cost-effective research pipelines.

Operational and procurement responses to tariff shifts that are reshaping supplier strategies, inventory practices, and international collaboration in laboratories

Tariff dynamics introduced in 2025 have created tangible pressures across procurement, contract operations, and cross-border research collaborations. Elevated duties on specific laboratory equipment, consumables, and chemical imports have prompted many organizations to re-evaluate supplier portfolios and renegotiate contracts to preserve continuity of operations. As a result, procurement teams are working more closely with scientific leads to prioritize critical items for stockpiling, explore alternative suppliers, and qualify regional distributors to mitigate single-source exposure.

At the operational level, some laboratories have adjusted maintenance and calibration schedules to optimize the lifecycle of existing instruments and avoid immediate capital replacement during periods of higher import costs. In addition, greater emphasis is being placed on localization of critical supplies and on building strategic inventory buffers for reagents and consumables. International collaborations face added administrative burdens as customs classifications and compliance checks have increased lead times. In response, institutions are strengthening supply chain governance, enhancing demand forecasting practices, and pursuing contractual terms that share tariff risk between buyers and suppliers to sustain research continuity.

Deep segmentation-driven insights that illuminate distinct requirements across end users, compound types, applications, and automation levels to guide strategic product and service alignment

Segmentation insights reveal differentiated needs and adoption patterns that should guide product development, service models, and go-to-market approaches. When viewed through the lens of end users, academic and research institutions typically prioritize flexibility, cost-effectiveness, and open integration with diverse instrument fleets, whereas pharmaceutical companies demand validated, scalable systems with rigorous compliance features and long-term service commitments. Biotech companies often seek modular solutions that can accommodate rapid pivots in project scope, while contract research organizations focus on high-throughput capacity and standardized workflows to serve multiple clients. Government and regulatory agencies emphasize chain-of-custody and long-term archival integrity for samples used in surveillance and public health research.

Analyzing compound type highlights further nuances: small molecules generally benefit from established, high-density storage and automated retrieval systems, while biologics require specialized temperature control and contamination prevention; within biologics, cell therapy products, gene therapy products, monoclonal antibodies, recombinant proteins, and vaccines each present unique handling and regulatory demands that influence container formats, cold chain protocols, and validation pathways. Application-based segmentation shows that use cases such as agrochemicals and material science have different throughput and environmental tolerance requirements compared with drug discovery activities; within drug discovery, discrete workflows like hit identification, lead optimization, preclinical research, and target validation impose specific sampling cadence, aliquot sizing, and integrity monitoring needs. Finally, automation level differentiates buyer readiness: organizations opting for fully automated systems invest in end-to-end digital workflows and higher upfront capital for long-term efficiency, while manual and semi-automated systems remain prevalent where flexibility, lower capital expenditure, or unique sample types preclude full automation. Understanding these intersecting segments enables vendors and users to align solution features, service levels, and pricing strategies to real operational requirements.

How regional scientific ecosystems and regulatory environments influence compound management priorities, support models, and adoption of automation across global markets

Regional dynamics shape how organizations prioritize investments, partnerships, and operational resilience in compound management. In the Americas, a concentration of large pharmaceutical R&D hubs and mature biotech ecosystems drives demand for high-throughput, validated systems and service models that support regulated development. This region also features a strong aftermarket for integration services and localized support networks, encouraging vendors to offer long-term service agreements and customization options. Europe, the Middle East & Africa presents a diverse landscape where multinationals operate alongside national research institutes and an emerging biotech sector; regulatory harmonization across parts of Europe contrasts with localized procurement rules elsewhere, shaping adoption curves for automation and advanced inventory systems. In this region, interest in compliance-ready, modular solutions is pronounced given the need to balance cross-border collaboration with local regulatory constraints.

Asia-Pacific remains characterized by rapid capacity expansion, significant investment in translational and clinical research, and energetic growth of biotech startups that often demand flexible, scalable compound management solutions. The supply chain footprint in this region also fosters manufacturing and component sourcing opportunities, which can lower lead times for certain equipment. Across all regions, variations in labor costs, regulatory complexity, and infrastructure maturity influence the choice between fully automated and semi-automated or manual approaches, and they create opportunities for differentiated service offerings such as remote diagnostics, regional spare parts inventories, and localized validation support.

Competitive dynamics and partnership trends revealing how hardware-software-service integration and application-focused innovation are shaping vendor differentiation and customer retention

Key company insights focus on strategic positioning, partnership models, and the areas where competitive differentiation is emerging. Market leaders that pair robust hardware portfolios with scalable software platforms and proven service delivery are best positioned to capture enterprise-level programs requiring long-term validation and uptime guarantees. Conversely, emerging vendors find traction by offering modular, upgradeable architectures that lower the barrier to automation for midsized laboratories and by emphasizing interoperability through open APIs that facilitate integration with laboratory information management systems. Strategic partnerships between instrument manufacturers, software providers, and third-party service organizations are increasingly common as companies seek to deliver end-to-end value propositions covering installation, validation, maintenance, and data management.

Additionally, some firms are investing in application-specific solutions that address the unique demands of biologics and cell and gene therapies, including temperature-controlled logistics and contamination control innovations. Service differentiation is also notable: providers that can offer rapid on-site support, predictive maintenance remotely enabled by IoT sensors, and tailored training for in-house technical staff tend to reduce downtime and build stronger customer retention. Finally, companies that demonstrate a commitment to sustainability through energy-efficient storage systems and consumable reduction initiatives are resonating with institutional buyers seeking to meet environmental and governance objectives.

Actionable strategic priorities for executives to strengthen interoperability, supply resilience, and data-driven operations in compound management environments

Industry leaders should take decisive actions to align compound management capabilities with scientific strategy and operational resilience. First, executives should prioritize interoperability and modularity when evaluating new equipment, ensuring that investments can be scaled or repurposed as scientific priorities change. Second, cross-functional governance structures that include procurement, scientific operations, quality, and IT should be established to streamline supplier qualification, manage tariff and supply chain risk, and enforce data integrity standards. Third, organizations should pilot data-rich initiatives that use analytics and IoT-enabled diagnostics to reduce unplanned downtime and optimize reagent utilization, thereby simultaneously improving throughput and lowering operational risk.

Moreover, leaders ought to assess their portfolio of suppliers and service agreements through scenario planning that accounts for regional sourcing variability and potential policy shifts. Investing in staff training and in-house validation capabilities will reduce dependency on external service providers and accelerate time-to-experiment. Finally, sustainability and compliance should be elevated as strategic imperatives; adopting energy-efficient storage technologies, reducing single-use plastic consumption where feasible, and documenting chain-of-custody practices will both reduce cost pressure over time and align the organization with evolving stakeholder expectations.

A rigorous mixed-methods approach combining practitioner interviews, technical literature review, and expert validation to derive practical operational insights and strategic recommendations

The research methodology underpinning this executive summary combined a structured review of primary and secondary inputs with expert validation to ensure relevance and practical applicability. Primary sources included interviews with laboratory managers, procurement heads, and technical leads across academic, biotech, contract research, government, and pharmaceutical organizations to capture firsthand operational challenges and procurement behaviors. Secondary inputs encompassed vendor technical literature, regulatory guidance documents, and peer-reviewed publications that describe evolving handling requirements for small molecules and complex biologics, as well as white papers on automation and data integration best practices.

These inputs were synthesized using a thematic analysis approach to identify recurring pain points, adoption enablers, and value levers. Cross-validation with experienced technologists and supply chain specialists ensured that operational recommendations were grounded in real-world constraints and opportunities. Care was taken to anonymize sensitive contributor information, and all conclusions emphasize qualitative trends and actionable insights rather than quantitative market estimates, enabling leaders to apply findings directly to technology selection, process redesign, and vendor negotiations.

A forward-looking synthesis explaining why compound management is now a strategic enabler of research velocity, sample integrity, and regulatory readiness for R&D organizations

In conclusion, compound management has evolved from a largely transactional back-office function to a strategic capability that materially influences research velocity, data integrity, and regulatory readiness. Advancements in automation, the growing prominence of biologics and cell and gene therapies, and increasing emphasis on data-driven maintenance and inventory control are converging to raise the bar for system interoperability, environmental controls, and service reliability. Organizations that proactively align procurement, scientific operations, and IT functions will be better positioned to capture the productivity gains offered by modern compound management systems and to mitigate risks associated with supply chain volatility and regulatory scrutiny.

Moving forward, decision-makers should treat compound management as an integral component of their research platform strategy-investing in modular, validated systems where appropriate, strengthening supplier and regional risk management, and leveraging analytics to optimize uptime and reagent use. By doing so, laboratories and development organizations can improve throughput, safeguard sample integrity, and support the translational goals that drive scientific and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Compound Management Market, by End User

  • 8.1. Academic And Research Institutions
  • 8.2. Biotech Companies
  • 8.3. Contract Research Organizations
  • 8.4. Government And Regulatory Agencies
  • 8.5. Pharmaceutical Companies

9. Compound Management Market, by Compound Type

  • 9.1. Biologics
    • 9.1.1. Cell Therapy Products
    • 9.1.2. Gene Therapy Products
    • 9.1.3. Monoclonal Antibodies
    • 9.1.4. Recombinant Proteins
    • 9.1.5. Vaccines
  • 9.2. Nucleotides
  • 9.3. Peptides
  • 9.4. Small Molecules

10. Compound Management Market, by Application

  • 10.1. Agrochemicals
  • 10.2. Drug Discovery
    • 10.2.1. Hit Identification
    • 10.2.2. Lead Optimization
    • 10.2.3. Preclinical Research
    • 10.2.4. Target Validation
  • 10.3. Material Science
  • 10.4. Specialty Chemicals

11. Compound Management Market, by Automation Level

  • 11.1. Fully Automated Systems
  • 11.2. Manual Systems
  • 11.3. Semi Automated Systems

12. Compound Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Compound Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Compound Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Compound Management Market

16. China Compound Management Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Arctoris Ltd.
  • 17.7. AXXAM S.p.A.
  • 17.8. Azenta US, Inc.
  • 17.9. Beckman Coulter Life Sciences
  • 17.10. BioAscent Discovery Ltd.
  • 17.11. BioIVT
  • 17.12. Biosero Inc.
  • 17.13. Brooks Automation, Inc.
  • 17.14. ChemBridge Corporation
  • 17.15. ChemDiv Inc.
  • 17.16. Collaborative Drug Discovery
  • 17.17. Compound Management Group
  • 17.18. Danaher Corporation
  • 17.19. Evotec SE
  • 17.20. Hamilton Company
  • 17.21. HighRes Biosolutions Inc.
  • 17.22. Labcyte Inc.
  • 17.23. LiCONiC AG
  • 17.24. OpenEye Scientific Software, Inc.
  • 17.25. PerkinElmer, Inc.
  • 17.26. SPT Labtech Ltd.
  • 17.27. Tecan Group Ltd.
  • 17.28. Titian Service Limited
  • 17.29. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPOUND MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPOUND MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 148. GCC COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 169. G7 COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 176. NATO COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)